Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antibodies by Design, a division of MorphoSys AG, and JPT Peptide Technologies GmbH, a subsidiary of Jerini AG, have entered into a co-marketing agreement for monoclonal antibodies and complementary services and products.
Subscribe to our email newsletter
The monoclonal antibodies will be provided by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan.
“MorphoSys’ unique antibody repertoire is the ideal complement to our immunology tools program which includes the peptide array platforms PepSpot and PepStar plus the novel PepMix technology for effective T-lymphocyte stimulation,” said Holger Wenschuh, managing director of JPT. “This co-marketing agreement will allow both companies to address new customers and offer them an even wider package of immunology services.”
Both JPT and MorphoSys are Germany-based biotechnology companies, with headquarters in Berlin and Munich, respectively. JPT is a leading peptide-based products and services supplier and MorphoSys is one of the world’s leading biotech companies focusing on fully human antibodies.